
Asmaa Ibrahim Gomaa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2096273/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World Journal of Gastroenterology, 2008, 14, 4300.	3.3	590
2	Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Review of Gastroenterology and Hepatology, 2009, 3, 353-367.	3.0	259
3	Diagnosis of hepatocellular carcinoma. World Journal of Gastroenterology, 2009, 15, 1301.	3.3	140
4	Hepatitis C in Egypt – past, present, and future. International Journal of General Medicine, 2017, Volume 10, 1-6.	1.8	130
5	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Responseâ€Based Approach. Hepatology, 2020, 72, 198-212.	7.3	92
6	Urinary Metabolic Biomarkers of Hepatocellular Carcinoma in an Egyptian Population: A Validation Study. Journal of Proteome Research, 2011, 10, 1828-1836.	3.7	88
7	Hepatitis C treatment: where are we now?. International Journal of General Medicine, 2017, Volume 10, 39-52.	1.8	86
8	Recent advances in multidisciplinary management of hepatocellular carcinoma. World Journal of Hepatology, 2015, 7, 673.	2.0	77
9	Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. British Journal of Cancer, 2017, 116, 448-454.	6.4	66
10	Comparing Staging Systems for Predicting Prognosis and Survival in Patients with Hepatocellular Carcinoma in Egypt. PLoS ONE, 2014, 9, e90929.	2.5	61
11	Contradicting interplay between insulin-like growth factor-1 and miR-486-5p in primary NK cells and hepatoma cell lines with a contemporary inhibitory impact on HCC tumor progression. Growth Factors, 2016, 34, 128-140.	1.7	49
12	Enhancing NK cell cytotoxicity by miR-182 in hepatocellular carcinoma. Human Immunology, 2016, 77, 667-673.	2.4	44
13	MiR-615-5p depresses natural killer cells cytotoxicity through repressing IGF-1R in hepatocellular carcinoma patients. Growth Factors, 2017, 35, 76-87.	1.7	40
14	GES: A validated simple score to predict the risk of HCC in patients with HCVâ€GT4â€associated advanced liver fibrosis after oral antivirals. Liver International, 2020, 40, 2828-2833.	3.9	31
15	Aiming at the Global Elimination of Viral Hepatitis: Challenges Along the Care Continuum. Open Forum Infectious Diseases, 2018, 5, ofx252.	0.9	22
16	<p>Intermediate stage hepatocellular carcinoma: a summary review</p> . Journal of Hepatocellular Carcinoma, 2019, Volume 6, 105-117.	3.7	21
17	Utility and cost-effectiveness of screening for hepatocellular carcinoma in a resource-limited setting. Medical Oncology, 2015, 32, 432.	2.5	19
18	Health: redefined. Pan African Medical Journal, 2018, 30, 292.	0.8	18

#	Article	IF	CITATIONS
19	Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma. World Journal of Hepatology, 2019, 11, 542-552.	2.0	18
20	Effectiveness of ravidasvir plus sofosbuvir in interferon-naÃ ⁻ ve and treated patients with chronic hepatitis C genotype-4. Journal of Hepatology, 2018, 68, 53-62.	3.7	17
21	Platelet-albumin-bilirubin score - a predictor of outcome of acute variceal bleeding in patients with cirrhosis. World Journal of Hepatology, 2020, 12, 99-107.	2.0	15
22	Ascites and alpha-fetoprotein improve prognostic performance of Barcelona Clinic Liver Cancer staging. World Journal of Gastroenterology, 2015, 21, 5654.	3.3	9
23	Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era. Arab Journal of Gastroenterology, 2018, 19, 26-32.	0.9	9
24	The Role of Monocyte/Macrophage and CXCR3 in Differentiation between Recurrent Hepatitis C and Acute Cellular Rejection Postliver Transplantation. Journal of Immunology Research, 2018, 2018, 1-7.	2.2	8
25	Outcomes of curative liver resection for hepatocellular carcinoma in patients with cirrhosis. World Journal of Gastrointestinal Oncology, 2021, 13, 424-439.	2.0	6
26	The Diagnostic Impact of C4d, CD68, and NF-κB Expression in the Differentiation Between Recurrent Hepatitis C and Acute Cellular Rejection After Liver Transplantation. Applied Immunohistochemistry and Molecular Morphology, 2016, 24, 639-647.	1.2	5
27	The Plasma and Serum Metabotyping of Hepatocellular Carcinoma in a Nigerian and Egyptian Cohort using Proton Nuclear Magnetic Resonance Spectroscopy. Journal of Clinical and Experimental Hepatology, 2017, 7, 83-92.	0.9	4
28	Decreased Incidence of Hepatocellular Carcinoma after Directly Acting Antiviral Therapy in Patients with Hepatitis C–Related Advanced Fibrosis and Cirrhosis. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 925-935.	3.7	4
29	Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6929-6934.	1.2	4
30	Optimised systematic review tool: Application to candidate biomarkers for the diagnosis of hepatocellular carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2022, , .	2.5	1
31	Fluorescence in-situ hybridization as a novel technique for rapid and sensitive detection of ascitic fluid infection. Egyptian Liver Journal, 2012, 2, 113-121.	0.6	0
32	Expression of SSX-1 and SSX-5 genes in the peripheral blood of patients with hepatocellular carcinoma. Egyptian Journal of Medical Human Genetics, 2014, 15, 45-51.	1.0	0
33	Prevalence and predictors of post-liver transplantation metabolic bone diseases. Clinical and Experimental Hepatology, 2021, 7, 286-292.	1.3	0